health insurance: COVID health insurance policies will also cover the cost of treatment for Omicron infection: Irdai

Insurance regulator Irdai said on Monday that health insurance policies that cover COVID treatment costs will also cover expenses for treating infections from Omicron.

“All health insurance policies issued by all general and health insurance companies that cover the cost of treatment for COVID-19 also cover the cost of treatment against the Omicron variant of COVID-19 in accordance with the terms and conditions of the contract police,” the Insurance Regulatory and Development Authority said. of India (IRDAI) said in a statement.

The regulator issued the directive to general and medical insurers given the growing number of cases of the Omicron variant.

The regulator also asked insurance companies to put in place an effective coordination mechanism with all their network providers and hospitals in order to make transparent cashless services available to all policyholders in the event of hospitalization and provide prompt services to all policyholders.

Also in April 2020, Irdai clarified that all indemnity health insurance products that cover hospitalization treatment costs offered by all general and health insurance companies cover hospitalization treatment costs because of the COVID-19.

So far, 1,700 cases of the Omicron variant of the coronavirus have been detected in 23 states and union territories, of which 639 have recovered or migrated, according to updated Union Health Ministry data. Monday.

Maharashtra has recorded the peak number of 510 cases, followed by Delhi (351), Kerala (156), Gujarat (136), Tamil Nadu (121) and Rajasthan (120).

India’s COVID tally rose to 3,49,22,882 with 33,750 new cases, according to data updated as of 8am.

The death toll climbed to 4,81,893 with 123 more fatalities, the data showed. Active cases rose to 1,45,582, or 0.42 percent of the total number of infections, while the national COVID-19 cure rate was recorded at 98.20 percent, the health ministry said.


Comments are closed.